CD261 Antibody (FITC)
494€ (0.1 mg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
CD261 Antibody (FITC)
category
Primary Antibodies
provider
Abbexa
reference
abx139973
tested applications
FCM
Description
CD261 Antibody is a Mouse Monoclonal against CD261.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | CD261 |
| Host | Mouse |
| Reactivity | Human |
| Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | FITC |
| Isotype | IgG1 |
| Clone ID | B841 |
| Size 1 | 0.1 mg |
| Tested Applications | FCM |
| Buffer | Stabilizing PBS solution containing 15 mM sodium azide. |
| Availability | Shipped within 5-12 working days. |
| Storage | Store in the dark at 2-8°C. Avoid exposure to light. Do not freeze. |
| Dry Ice | No |
| UniProt ID | O00220 |
| Gene ID | 8797 |
| Alias | DR4,APO2,CD261,TRAILR1,TRAILR-1,Death receptor 4,NF-related apoptosis-inducing ligand receptor 1 |
| Background | Antibody anti-TNFRSF10A |
| Status | RUO |
| Note | Concentration: 0.1 mg/ml - |
Descripción
TNFRSF10A (TNF receptor superfamily member 10a), also known as TRAIL receptor 1 (TRAIL-R1) or death receptor 4 (DR4), is a member of the TNF receptor superfamily. TNFRSF10A is primarily recognized for its ability to bind to TRAIL (TNF-related apoptosis-inducing ligand), a pro-apoptotic ligand that induces cell death selectively in transformed or cancerous cells. TRAIL and its receptors are part of a critical signaling axis that regulates apoptosis, especially in response to cellular stress and immune-mediated cell targeting. The receptor is expressed on the cell surface of a variety of tissues and has been implicated in numerous physiological processes, including tumor surveillance, immune response, and inflammatory regulation. Due to its ability to mediate apoptosis in abnormal cells while sparing normal cells, TNFRSF10A has gained attention in cancer research as a therapeutic target
Related Products
Human TNFRSF10A (Tumor necrosis factor receptor superfamily member 10A) ELISA Kit
Ver Producto
TNFRSF10A antibody
Ver Producto